en · de · es · pt
bpc-157-notes.peptides6579.com › Blog › Identity And Chemical Background — Background and Details

Identity And Chemical Background — Background and Details

By Editorial Desk · published 2025-12-21 · last reviewed 2026-01-10 · Blog

If you have been reading about BPC 157 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-01-10. Numbers and descriptions here follow the published literature rather than marketing material.

Identity And Chemical Background

The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.

Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.

Origin and Peptide Identity

BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.

Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.

Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.

Bpc-157 at a glance

PropertyValueNotes
Molecular formulaC62H98N16O22Approximate, for sequence GEPPPGKPADDAGLV
Molecular mass~1419 DaNeutral form
AppearanceWhite to off-white powderLyophilized solid
SolubilitySoluble in waterAlso soluble in aqueous buffers
Typical storage-20 CDry powder, protected from moisture

Background and Chemical Identity

BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.

The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.

Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.

Related pages on this site

BPC-157 Identity and Origin

Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.

Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.

Reference notes

Comparative bullet-lead analysis was used by the FBI for over four decades, starting with the John F. Kennedy assassination in 1963. The theory was that each batch of ammunition possessed a chemical makeup so distinct that a bullet could be traced back to a particular batch or even a specific box. Internal studies and an outside study by the National Academy of Sciences found that the technique was unreliable due to improper interpretation, and the FBI abandoned the test in 2005. Forensic dentistry has come under fire: in at least three cases bite-mark evidence has been used to convict people of murder who were later freed by DNA evidence. A 1999 study by a member of the American Board of Forensic Odontology found a 63 percent rate of false identifications and is commonly referenced within online news stories and conspiracy websites. The study was based on an informal workshop during an ABFO meeting, which many members did not consider a valid scientific setting. The theory is that each person has a unique and distinctive set of teeth, which leave a pattern after biting someone. They analyze the dental characteristics such as size, shape, and arch form. Police Access to Genetic Genealogy Databases: There are privacy concerns with the police being able to access personal genetic data that is on genealogy services. Individuals can become criminal informants to their own families or to themselves simply by participating in genetic genealogy databases.

== History == The drug was developed by Takeda. It got US and European orphan drug status for multiple myeloma in 2011, and for AL amyloidosis in 2012. Takeda submitted a US new drug application for multiple myeloma in July 2015. In September 2015, the U.S. Food and Drug Administration (FDA) granted ixazomib combined with lenalidomide and dexamethasone a priority review designation for multiple myeloma. On 20 November 2015, the FDA approved this combination for second-line treatment. The request for marketing authorisation in Europe was initially refused by the European Medicines Agency (EMA) in May 2016 due to insufficient data showing a benefit of treatment. After Takeda requested a re-examination, the EMA granted a marketing authorisation on 21 November 2016 on the condition that further efficacy studies be conducted. The approval indication is the same as in the US.

ASBMB Award for Exemplary Contributions to Education ASBMB Leadership Awards ASBMB–Merck Award ASBMB Young Investigator Award Avanti Award in Lipids Bert and Natalie Vallee Award in Biomedical Science DeLano Award for Computational Biosciences Earl and Thressa Stadtman Distinguished Scientist Award Earl and Thressa Stadtman Young Scholar Award Herbert Tabor Research Award Mildred Cohn Award in Biological Chemistry - The Mildred Cohn Award in Biological Chemistry was established in 2013 to honor the scientific achievements of Mildred Cohn. Cohn was the first female president of the society, in 1978. The award of $5,000 is presented annually to a scientist who has made substantial advances in understanding biological chemistry using innovative physical approaches. The recipient is expected to deliver the Mildred Cohn Award lecture at the annual meeting. Ruth Kirschstein Diversity in Science Award The Alice and C. C. Wang Award in Molecular Parasitology Walter A. Shaw Young Investigator Award in Lipid Research William C. Rose Award

Sources: en.wikipedia.org

Reference notes

=== They Hunger 2: Rest in Pieces === The protagonist begins the game where the last left off: unarmed and trapped, however just as a zombie is about to enter his cell, the player is saved by a state police officer with a military-equipped truck. Still unarmed, the player is forced to restock his arsenal himself (though it is possible to re-enter the police station and regain several lost weapons). The player soon after enters the sewers. There he encounters bizarre aquatic creatures. He also encounters several state police officers who have been zombified after arriving at the town. The player later makes it to the Rockwell water treatment plant. It becomes apparent that the military has taken notice of the problem and had started sending troops in to take care of the zombies and determine what was happening to the civilians. However, the player does not actually meet up with any living soldiers (as they are quickly killed by zombies when encountered) until the next episode. A major part of this episode is spent exploring 'Rockwell Asylum for the Criminally Insane' operated by Dr. Franklin (who could possibly have created the headcrabs from the previous chapter). Once inside, the player meets Alfred, Dr. Franklin's former assistant, who tells the player that it was he and Dr. Franklin that discovered strange contaminants in the city water that brings anyone alive or dead to an intermediate state of half life. He tells the player that Dr. Franklin was trying to figure out how it was causing the zombies but ended up being infected too. The player then enters Dr.

==== Injectable glucagon-like peptide analogs and agonists ==== Glucagon-like peptide (GLP) agonists bind to a membrane GLP receptor. As a consequence, insulin release from the pancreatic beta cells is increased. Endogenous GLP has a half-life of only a few minutes, thus an analogue of GLP would not be practical. As of 2019, the AACE lists GLP-1 agonists, along with SGLT2 inhibitors, as the most preferred anti-diabetic agents after metformin. Liraglutide in particular may be considered first-line in diabetic patients with cardiovascular disease, as it has received FDA approval for reduction of risk of major adverse cardiovascular events in patients with type 2 diabetes. In a 2011 Cochrane review, GLP-1 agonists showed approximately a 1% reduction in HbA1c when compared to placebo. GLP-1 agonists also show improvement of beta-cell function, but this effect does not last after treatment is stopped. Due to shorter duration of studies, this review did not allow for long-term positive or negative effects to be assessed.

Assembling phenethylamine structures for synthesis of compounds such as epinephrine, amphetamines, tyrosine, and dopamine by adding the beta-aminoethyl side chain to the phenyl ring is possible. This can be done via Friedel-Crafts acylation with N-protected acyl chlorides when the arene is activated, or by Heck reaction of the phenyl with N-vinyloxazolone, followed by hydrogenation, or by cross-coupling with beta-amino organozinc reagents, or reacting a brominated arene with beta-aminoethyl organolithium reagents, or by Suzuki cross-coupling.

Sources: en.wikipedia.org

Frequently asked questions

What does the abbreviation BPC-157 stand for?

The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.

Is BPC-157 the same as the gastric protein it is named after?

No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.

What form is the peptide usually distributed in?

It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.

What is BPC-157 chemically?

It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.

Network